Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
AstraZeneca posts mixed results from recent Imfinzi trials
(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday. The FTSE 100 pharmaceuticals giant said the ADJUVANT BR.31 trial, sponsored by the Canadian Cancer Trials Group (CCTG), investigated Imfinzi in early-stage non-small cell lung cancer (NSCLC).
It said the trial did not achieve statistical significance in its primary endpoint of disease-free survival (DFS) compared to placebo in patients with PD-L1 expression on 25% or more tumour cells.
Despite that, the safety profile of Imfinzi remained consistent with previous data, and no new safety concerns were identified.
Detailed findings would be presented at an upcoming medical meeting, AstraZeneca said.
"We are disappointed in the ADJUVANT BR.31 results," said the company's executive vice-president of oncology research and development, Susan Galbraith.
"Imfinzi has helped change the treatment landscape and achieved multiple positive Phase III trials for patients with earlier stages of lung cancer.
"We are committed to addressing the remaining unmet need in lung cancer through our broad development programme."
In contrast, the NIAGARA phase three trial yielded positive results for Imfinzi in combination with chemotherapy for muscle-invasive bladder cancer (MIBC).
The study showed a statistically significant and clinically meaningful improvement in event-free survival (EFS) and overall survival (OS) compared to neoadjuvant chemotherapy alone.
Patients received Imfinzi alongside chemotherapy before cystectomy, followed by Imfinzi as an adjuvant monotherapy.
The combination was generally well-tolerated, with no new safety concerns and no increase in adverse event-related discontinuations.
AstraZeneca said those results would also be discussed at a forthcoming medical meeting, and shared with regulatory authorities.
"The NIAGARA results support our strategy to move immunotherapy to the early stages of cancer treatment," Susan Galbraith added.
"This perioperative regimen with Imfinzi improved survival and reduced the rate at which patients experience disease recurrence or progression.
"We are eager to bring this regimen with the potential to transform the standard of care to patients as soon as possible."
Imfinzi was still the only approved immunotherapy for unresectable, stage three NSCLC in patients whose disease had not progressed following chemoradiotherapy, based on the PACIFIC phase three trial, AstraZeneca noted.
It was also under investigation for various other early-stage lung cancer settings.
At 0825 BST, shares in AstraZeneca were up 0.34% at 12,522p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.